Brokers have updated their ratings and price targets on Neuren Pharmaceuticals Ltd (ASX: NEU) shares and others this earnings season.
Bronwyn Allen is a Copy Editor and Writer at Motley Fool Australia. With 25 years of experience in journalism and media relations, she specializes in finance-related topics, including investment strategies, commodities markets, and personal finance. Bronwyn's insights and expertise have been featured in Kanebridge Ltd, MSN, and Fool.













